WO2017191924A1 - Composition de nano-émulsion contenant un émulsifiant à base de polyglycéryle - Google Patents

Composition de nano-émulsion contenant un émulsifiant à base de polyglycéryle Download PDF

Info

Publication number
WO2017191924A1
WO2017191924A1 PCT/KR2017/004427 KR2017004427W WO2017191924A1 WO 2017191924 A1 WO2017191924 A1 WO 2017191924A1 KR 2017004427 W KR2017004427 W KR 2017004427W WO 2017191924 A1 WO2017191924 A1 WO 2017191924A1
Authority
WO
WIPO (PCT)
Prior art keywords
nanoemulsion composition
polyglyceryl
nanoemulsion
less
stearate
Prior art date
Application number
PCT/KR2017/004427
Other languages
English (en)
Korean (ko)
Inventor
김수일
신홍주
정연수
이창근
김정환
박영호
Original Assignee
(주)아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)아모레퍼시픽 filed Critical (주)아모레퍼시픽
Publication of WO2017191924A1 publication Critical patent/WO2017191924A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/046—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size

Definitions

  • the present specification relates to a nanoemulsion composition
  • a nanoemulsion composition comprising a polyglyceryl-based emulsifier and a preparation method thereof.
  • Functional materials used in the fields of cosmetics, pharmaceuticals, food and beverages are denatured by external environmental factors (light, heat, oxygen, etc.) despite their excellent effects, or they are insoluble in water and general organic solvents. Often limited.
  • surfactants or emulsifiers are used to stabilize the solution through emulsions or encapsulation. In this case, unstable phenomena such as agglomeration of micelles or separation of functional substances often occur. There may be limitations in using it.
  • cosmetics are often formulated by combining substances that do not dissolve with each other, such as water-soluble components and fat-soluble components, so that emulsification and dispersion techniques are very important, and the purpose and method of use are also subdivided. Therefore, various emulsification techniques have been developed in the cosmetic field. Has been. Research is continuously underway to add new value to cosmetics using various cosmetic formulation technologies. Emulsions are one of the most representative formulation and research systems in the cosmetic industry. Many researches have been conducted on maintaining stability in emulsion. As the particle size is small and the distribution is uniform, the long-term stability is excellent. Therefore, the nanoemulsion with small particle size and even distribution is actively researched. I'm losing.
  • Conventional nanoemulsion preparation methods include a high-pressure emulsification method for emulsifying an emulsifier by mechanical force, a full-phase temperature emulsification method, a D-phase emulsification method, etc., which are methods using interfacial chemical properties.
  • the high pressure emulsification method has the advantage of being capable of continuous manufacturing and easy mass production, but it takes a lot of time and place, and it is expensive in terms of equipment because it is expensive.
  • the method using the interfacial chemical properties has a restriction that must use a polyoxyethylene (polyoxyethylene, POE) system.
  • the emulsifiers used to prepare nanoemulsions have been the mainstream of PEG-based compounds added with ethylene oxide.
  • the present inventors have completed the present invention while solving the problems of the prior art as described above, while studying for the production of nanoemulsion excellent in terms of stability.
  • nanoemulsion composition that is significantly more stable than conventional nanoemulsions through the combination of polyglyceryl-based emulsifiers.
  • purpose of preparing nanoemulsion using only homomixer is to save time and cost, and to provide nanoemulsion without skin irritation by limiting PEG-based raw materials. have.
  • the present invention provides a nanoemulsion composition comprising polyglyceryl stearate as an emulsifier.
  • the present invention provides a method including a dispersion using a homomixer as a method of preparing the nanoemulsion composition.
  • Nanoemulsion composition according to an aspect of the present invention is significantly increased stability compared to the conventional nanoemulsion composition, significantly reduced in terms of time and cost compared to the conventional manufacturing method, to exclude skin irritation by PEG-based compounds It works.
  • Example 1 is a view showing a distribution over time with respect to the particle size of the nanoemulsion composition according to Example 3 of the present specification at room temperature.
  • Example 2 is a view showing the distribution over time in the refrigeration conditions for the particle size of the nanoemulsion composition according to Example 3 of the present specification.
  • Figure 3 is a view showing the distribution over time in 45 °C conditions for the particle size of the nanoemulsion composition according to Example 3 of the present specification.
  • the nanoemulsion disclosed herein refers to an emulsion having an average particle size of nano unit among liquid-liquid dispersion systems in which one or more liquid phases are not mixed in one liquid phase, and generally have a size distribution of several ⁇ m to several hundred ⁇ m.
  • nanoemulsions disclosed herein include those having an average particle size of 400 nm or less. The smaller the particle size and the more uniform the particle size distribution, the more stable it can be seen.
  • the average particle size disclosed herein refers to the average diameter of the particles, and since the particles are three-dimensional objects, they include particle sizes calculated using the equivalent sphere concept to measure the diameter when the particles are not perfectly spherical. will be. For example, spheres of the same maximum length, spheres of the same minimum length, spheres of the same mass, spheres of the same volume, spheres of the same surface area, spheres passing through the same sieve aperture, spheres having the same sedimentation velocity, and the like. Particle size can be calculated from the equivalent spherical diameter in terms of equivalent spherical shape having the same characteristics, and the average particle size can be seen as an average value for these particle sizes of the particles.
  • the average particle size also includes a particle size measured by a dynamic light scattering (DLS) method.
  • the dynamic light scattering method includes a method of determining particle size by Brownian motion of particles, and a method of determining particle size by reading wavelength intensity of scattered light that changes per predetermined time interval.
  • Light used in the method may include a laser.
  • a formula for determining the particle size may be used as commonly used, and the formula includes a Stoke-Einstein relation regarding the diffusion coefficient.
  • PDI disclosed herein refers to a polydispersity index, which means a weight average molecular weight (Mw) divided by a number average molecular weight (Mn) (Mw / Mn).
  • Mw weight average molecular weight
  • Mn number average molecular weight
  • a weight average molecular weight and a number average molecular weight are experimental values which can be obtained by experiment.
  • the larger the PDI the wider the molecular weight distribution tends to be unstable on the nanoemulsion, and the lower the PDI, the narrower and more uniform the molecular weight distribution.
  • Analogous ceramides disclosed herein include compounds having the same or similar structure as natural ceramides, including synthetic ceramides having the same or similar function as natural ceramides.
  • the present invention provides a nanoemulsion composition comprising polyglyceryl stearate as an emulsifier.
  • polyglyceryl stearate is a compound belonging to a polyglycerin fatty acid ester, and is a compound obtained by esterifying a stearic acid, which is one of fatty acids, to a polyglycerol polymerized with one or more glycerin, and has a general meaning of poly Includes all glyceryl stearate.
  • the number of glycerin to be polymerized is not limited, and the number of stearic acid is also not limited, and glycerin or stearic acid includes a substituent, and all of its variants and isomers.
  • polyglyceryl stearate examples include polyglyceryl-4 iso stearate, polyglyceryl-6 mono stearate, polyglyceryl-6 iso stearate, polyglyceryl-10 mono stearate, poly Glyceryl-10 monoisostearate, polyglyceryl-10 distearate, polyglyceryl-10 diiso stearate, polyglyceryl-10 tristearate, polyglyceryl-3 alkylglucose monostearate, polyglycerol Reel-3 alkylglucose distearate, polyglyceryl-3 alkylglucose tristearate, and the like.
  • the polyglyceryl stearate preferably comprises polyglyceryl-10 stearate and polyglyceryl-3 alkylglucose distearate, more preferably polyglyceryl-10 stearate and polyglyceryl-3 methylglucose Distearate.
  • the polyglyceryl stearate may be one kind or two or more kinds.
  • the polyglyceryl stearate may include polyglyceryl-10 stearate and polyglyceryl-3 alkylglucose distearate.
  • the polyglyceryl stearate may be 0.1 to 10% by weight relative to the total weight of the nanoemulsion composition.
  • the polyglyceryl stearate is 0.1 wt% or more, 0.2 wt% or more, 0.3 wt% or more, 0.4 wt% or more, 0.5 wt% or more, 0.6 wt% or more, 0.7 wt% or more, based on the total weight of the nanoemulsion composition, At least 0.8 weight percent, at least 0.9 weight percent, at least 1.0 weight percent, at least 1.5 weight percent, at least 2.0 weight percent, at least 2.5 weight percent, at least 3.0 weight percent, at least 3.5 weight percent, at least 4.0 weight percent, at least 4.5 weight percent, At least 5.0 weight percent, at least 5.5 weight percent, at least 6.0 weight percent, at least 6.5 weight percent, at least 7.0 weight percent, at least 7.5 weight percent, at least 8.0 weight percent, at least 8.5 weight percent, at least
  • wt% or less 0 wt% or less, 1.5 wt% or less, 1.0 wt% or less, 0.9 wt% or less, 0.8 wt% or less, 0.7 wt% or less, 0.6 wt% or less, 0.5 wt% or less, 0.4 wt% or less, 0.3 wt% or less, 0.2 wt% or less, or 0.15 wt% or less, and preferably 2 wt%.
  • the polyglyceryl stearate may be composed of polyglyceryl-10 stearate and polyglyceryl-3 alkylglucose distearate, polyglyceryl-10 stearate: polyglycerol
  • the weight ratio of reyl-3 alkylglucose distearate may be 7: 1 to 1: 7.
  • the weight ratio is not limited thereto, and is not limited to 7: 1 or more, 7: 2 or more, 7: 3 or more, 7: 4 or more, 7: 5 or more, 7: 6 or more, or 1: 1 or 1: 7 or less.
  • the alkyl of the polyglyceryl-3 alkylglucose distearate may be C 1 to C 6 alkyl.
  • the alkyl may preferably be methyl.
  • the stearate includes monostearate, distearate, tristearate, tetrastearate, pentastearate, hexastearate, heptastearate, octastearate, nonastearate, decastearate, preferably May be distearate.
  • the nanoemulsion composition may further comprise a lipid component.
  • the lipid component is not particularly limited, and may include all lipid components that can be generally used in the art.
  • the lipid component may be any one or more selected from the group consisting of ceramide, cholesterol, and fatty acids.
  • the fatty acid is not particularly limited and includes stearic acid.
  • the weight ratio of ceramide to polyglyceryl stearate may be 1: 1 to 1:20.
  • the weight ratio is not limited to 1: 1 or more, 1: 2 or more, 1: 3 or more, 1: 4 or more, 1: 5 or more, 1: 6 or more, 1: 7 or more, 1: 8 or more, 1: 9 or less, 1:10 or more, 1:20 or less, 1:15 or less, 1:10 or less, 1: 9 or less, 1: 8 or less, 1: 7 or less, 1: 6 or less, or 1: 5 or less It may be preferably 1:10.
  • the ceramide may be 0.01 to 1% by weight relative to the total weight of the nanoemulsion. It is not specifically limited to the said weight%, 0.01 weight% or more, 0.02 weight% or more, 0.03 weight% or more, 0.04 weight% or more, 0.05 weight% or more, 0.06 weight% or more, 0.07 weight% or more, 0.08 weight% or more, At least 0.09 weight percent, at least 0.1 weight percent, at least 0.2 weight percent, at least 0.3 weight percent, at least 0.4 weight percent, at least 0.5 weight percent, at least 0.6 weight percent, at least 0.7 weight percent, at least 0.8 weight percent, at least 0.9 weight percent, Or 0.95 wt% or less, 1.0 wt% or less, 0.9 wt% or less, 0.8 wt% or less, 0.7 wt% or less, 0.6 wt% or less, 0.7 wt% or less, 0.5 wt% or less, 0.4 wt% or less, 0.3
  • the ceramide may include natural ceramide or synthetic ceramide.
  • the synthetic ceramide may include pseudoceramide, and may include hydroxypropyl bispalmitamide MEA represented by the following Chemical Formula 1.
  • the nanoemulsion composition may further include any one or more of C 2 to C 8 polyhydric alcohol or glycerin.
  • the alcohol is propanol, but is not limited thereto.
  • the polyhydric alcohol may be a dihydric alcohol, more preferably propanediol.
  • the nanoemulsion composition may be a cosmetic composition.
  • the present invention may be a cosmetic composition comprising the nanoemulsion composition.
  • the nanoemulsion composition may be a mist formulation.
  • the nanoemulsion composition may have an average particle size of 400 nm or less.
  • the average particle size is 400 nm or less, 380 nm or less, 350 nm or less, 33 nm or less, 300 nm or less, 280 nm or less, 250 nm or less, 220 nm or less, 200 nm or less, 190 nm or less, 180 nm or less, 170 nm Or less, 160 nm or less, 150 nm or less, 140 nm or less, 130 nm or less, 120 nm or less, 110 nm or less, 100 nm or less, 80 nm or less, 50 nm or less, 30 nm or less, or 10 nm or less, preferably Preferably from 50 to 250 nm, more preferably from 150 to 180 nm.
  • the nanoemulsion composition may have a polydispersity index (PDI) of 0.55 or less.
  • PDI polydispersity index
  • the PDI is 0.55 or less, 0.5 or less, 0.45 or less, 0.4 or less, 0.35 or less, 0.3 or less, 0.29 or less, 0.28 or less, 0.25 or less, 0.24 or less, 0.22 or less, 0.21 or less, 0.2 or less, 0.18 or less, 0.15 or less, or 0.1 It may be less than, preferably 0.18 to 0.4, more preferably 0.2 to 0.29.
  • the nanoemulsion composition may be stably maintained for at least 16 weeks at a temperature of 4 °C or 45 °C.
  • the minimum 16 weeks is not limited thereto, and may be 16 weeks or more, 17 weeks or more, 18 weeks or more, 19 weeks or more, 20 weeks or more, or 25 weeks or more.
  • the nanoemulsion composition may be stable for at least 4 weeks under the conditions of 12 hours alternately -10 °C and 45 °C.
  • the minimum 4 weeks is not limited thereto, and may be at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 8 weeks, at least 12 weeks, or at least 16 weeks.
  • the nanoemulsion composition may not include a polyethylene glycol (PEG) -based compound.
  • PEG polyethylene glycol
  • Formulation of the nanoemulsion composition is not particularly limited, but can be used in hair, nails, and oral cavity including skin, mucous membranes, scalp, hair, and the like, for example, supple cosmetics, nourishing cosmetics, lotions, creams, packs, gels, Compositions selected from patches, sprays or mists, compositions selected from lipsticks, makeup bases, or foundations, compositions selected from shampoos, rinses, body cleansers, toothpastes, mouthwashes, or hair tonics, gels, mousses, etc. It comprises a hair composition selected from hair dressing, wool, hair dye.
  • the present invention may further include surfactants, emulsifiers, excipients, suspending agents, coloring agents, flavoring agents, oils, waxes, polyols and other additives generally used to prepare emulsions, and there is no particular limitation. .
  • the nanoemulsion composition according to one aspect of the present invention is significantly more stable than other nanoemulsions
  • stability verification was performed through Examples and Experimental Examples, and as a result, the nanoemulsion composition according to one aspect of the present invention had a particle size. It was found to be very small compared to other nanoemulsions in terms of surface area, and the PDI surface was significantly lower than other nanoemulsions (see Table 3).
  • Figures 1 to 3 the nanoemulsion composition according to one aspect of the present invention can be seen that the stability is remarkable in terms of stability compared to the conventional nanoemulsion is maintained for more than 16 weeks.
  • the present invention as a method of preparing the nanoemulsion composition, it can provide a method including dispersion using a homomixer (homomixer).
  • the homomixer is a device for homogeneously mixing and dispersing two or more materials, and generally, any one used in the art may be used, and the rpm is preferably 500 or more, but is not limited thereto.
  • An example of the manufacturing method by the said method is as follows.
  • an aqueous phase including a water-soluble physiologically active ingredient, a humectant, and purified water is prepared, and the dissolution is performed in an emulsification tank capable of temperature control and stirring by a conventional method, and may be stirred or heated as necessary.
  • the heating temperature is 50-80 ° C., preferably 70-75 ° C., so that other components can be sufficiently dissolved in the purified water.
  • an oil phase part including a biolipid component, an emulsifier and an oil is prepared.
  • the production of the oil phase can also be stirred or heated as necessary, similarly to the water phase.
  • the heating temperature is 50-80 ° C., preferably 70-75 ° C., so that the other components can be sufficiently dissolved in the oil.
  • an oil phase part is added to the water phase part to prepare a nanoemulsion.
  • using a homo mixer can be stirred for 5-10 minutes at a speed of 8000 to 12000rpm, preferably 10000rpm to produce a nano-sized emulsion through the primary emulsification. After cooling slowly to prepare a nanoemulsion composition.
  • the nanoemulsion is usually used in the manufacture of a high pressure emulsifier (Microfluidizer), because it is not possible to stably manufacture the nanoemulsion using only a homomixer.
  • the high pressure emulsification method is a method of making a nanoemulsion by applying physically strong force, which requires a high pressure emulsifier (Microfluidizer), which consumes a lot of time and money.
  • the preparation of the primary preemulsion is to form a micro-sized emulsion via primary emulsification by performing agitation for 3 to 10 minutes at a speed of 2000 to 4000 rpm, preferably 3000 rpm using a homo mixer in a vacuum emulsification tank. Is done.
  • the present invention since it is possible to produce a stable nanoemulsion using a homomixer without a high pressure emulsifier, it is much more advantageous than the conventional method for producing a nanoemulsion in terms of time and cost.
  • the conventional method for producing a nanoemulsion in terms of time and cost.
  • the aqueous phase containing the water-soluble physiologically active ingredient, humectant and purified water was dissolved in an emulsification tank by heating (70 ° C.) to dissolve.
  • the oil phase portion containing the biolipid component, emulsifier and oil was stirred in another emulsifier and heated (70 ° C.) to dissolve.
  • an oil phase part was added to the water phase part, and a stirring was performed for 5 minutes at a speed of 10000 rpm using a homo mixer to produce a nano-sized emulsion, and then gradually cooled to prepare a nanoemulsion composition.
  • the weight percentages of the aqueous phase, oil phase, and total nanoemulsion used are shown in the table below.
  • ceramide of the biolipid component hydroxypropyl bispalmitamide MEA, which is a pseudo ceramide, was used.
  • Example 1 Example 2
  • Example 3 Example 4
  • Example 5 Example 6
  • Example 7 Example 8
  • Example 9 Purified water Remaining amount Remaining amount Remaining amount Remaining amount Remaining amount Remaining amount Remaining amount Remaining amount Remaining amount Disodium ID 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 Polyglyceryl-10 Stearate 0.5 One One 0.2 0.8 One - 2 - Polyglyceryl-3 Methylglucose Distearate 0.5 One One 0.8 0.2 - One - 2 Polyglyceryl-10 Behenate / Eicosadiate - - - - - - - - - Methoxypig-114 / polyepsiloncaprolactone - - - - - - - - Hydroxypropyl Bispalmitamide MEA 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
  • the average particle size and particle size distribution of the nanoemulsions prepared by the above Examples and Comparative Examples were measured using a dynamic light scattering method (Dynamic Light Scattering, Instrument Model: Zetasizer Nano ZS, Malvern, UK). The scattering angle was fixed at 90 degrees and the measurement temperature was maintained at 25 degrees.
  • Example 6 Polyglyceryl-10 Stearate 1% 295.6 0.541
  • Example 7 Polyglyceryl-3 Methylglucose Distearate 1% 370.3 0.48
  • Example 1 0.5% polyglyceryl-10 stearate, 0.5% polyglyceryl-3 methylglucose distearate 167.6 0.268
  • Example 8 Polyglyceryl-10 Stearate 2% 282 0.445
  • Example 9 Polyglyceryl-3 Methylglucose Distearate 2% 300.5 0.419
  • Example 2 1% polyglyceryl-10 stearate, 1% polyglyceryl-3 methylglucose distearate 176.6 0.272
  • Example 3 0.5% polyglyceryl-10 stearate, 0.5% polyglyceryl-3 methylglucose distearate, 10% propanediol, 3% glycerin 158.02 0.219 Comparative Example 1 Polyglyceryl-10
  • the prepared nanoemulsion was stored in a thermostat at room temperature (21 ° C-23 ° C) and 45 ° C for 2 months to observe the appearance change of the nanoemulsion.
  • room temperature 21 ° C-23 ° C
  • 45 ° C 45 ° C for 2 months to observe the appearance change of the nanoemulsion.
  • After keeping for 12 hours in a constant temperature bath and kept for 12 hours, and maintained for 12 hours and then again for 12 hours, and then cooled to -10 °C and maintained for 12 hours in a thermostat for 2 months after storage of the nanoemulsion The change in appearance was observed. The results are shown in the table below.
  • Examples 1 to 5 showed good stability at room temperature, 45 ° C., or circulating conditions.
  • Examples 6 and 7 were stable for 1 week at room temperature and 45 ° C.
  • Examples 8 and 9 were stable for 1 week at room temperature and 45 ° C., and up to 3 days in circulating conditions
  • Comparative Examples 1 to 3 were room temperature Stable emulsion conditions were not maintained at both 45 ° C. and cycling conditions.
  • Example 3 is very good in terms of average particle size and PDI value, and also good in terms of stability regardless of temperature, the nanoemulsion of Example 3 Further stability assessments were made.
  • the particle size and the PDI value of the nanoemulsion of Example 3 were observed to change over time and the results are shown in the table below. This is confirmed by the above-mentioned dynamic laser light scattering method.
  • the results of the table below shows that the average particle size and PDI values of the nanoemulsion of Example 3 were maintained up to 16 weeks after preparation.
  • Example 1 is a view showing the particle distribution of the Example 3 nanoemulsion in consideration of the average particle size and PDI value change in the table, it can be seen that the particle size and PDI is maintained even after a time until 16 weeks after the preparation of the nanoemulsion composition .
  • Example 2 and 3 show the particle distribution of the nanoemulsion of Example 3 at 4 ° C. and 45 ° C., respectively, and it can be seen that the particle distribution is excellently maintained up to 16 weeks even under refrigeration conditions and high temperature conditions.
  • the nanoemulsion of Example 3 targets 30 healthy adult men and women who do not have psoriasis, acne, eczema, and other skin diseases (except those who are pregnant, nursing mothers, contraceptives or antihistamines).
  • a closed patch test was conducted. 20 ⁇ l of the nanoemulsion composition of Example 3 was patched on the back of the subject using an IQ chamber (Chemotechique MB Diagnostics, Sweden). After 48 hours or 72 hours, the patch was removed and the skin reaction was read for 30 minutes to 24 hours. Skin response readings were performed according to the following table, which is a modified test standard referring to the test standards of DTFA guidline (1981) and Frosch & Kligman (1979).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition de nano-émulsion ayant une stabilité améliorée au moyen d'une combinaison d'émulsifiants à base de polyglycéryle et un procédé de préparation de celle-ci. La composition de nano-émulsion selon la présente invention présente des caractéristiques particulièrement excellentes par rapport à une nano-émulsion conventionnelle en termes de taille et de distribution de particules ; le procédé de préparation de la nano-émulsion est plus économique et plus pratique qu'un procédé conventionnel ; et la composition de nano-émulsion est également excellente en termes de sécurité en raison de la restriction de l'utilisation d'un composé à base de PEG et, en conséquence, la composition de nano-émulsion et son procédé de préparation selon la présente invention peuvent être largement utilisés dans différents domaines.
PCT/KR2017/004427 2016-05-02 2017-04-26 Composition de nano-émulsion contenant un émulsifiant à base de polyglycéryle WO2017191924A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0054078 2016-05-02
KR1020160054078A KR102541257B1 (ko) 2016-05-02 2016-05-02 폴리글리세릴계 유화제를 포함하는 나노에멀젼 조성물

Publications (1)

Publication Number Publication Date
WO2017191924A1 true WO2017191924A1 (fr) 2017-11-09

Family

ID=60203702

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/004427 WO2017191924A1 (fr) 2016-05-02 2017-04-26 Composition de nano-émulsion contenant un émulsifiant à base de polyglycéryle

Country Status (2)

Country Link
KR (1) KR102541257B1 (fr)
WO (1) WO2017191924A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113797105A (zh) * 2021-08-24 2021-12-17 金发拉比妇婴童用品股份有限公司 一种温和安全型复合乳化剂及其应用
CN114681351A (zh) * 2022-04-01 2022-07-01 广州市娇兰化妆品有限公司 一种具有三重作用的类神经酰胺提取物的纳米乳液及其制备方法与应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101891953B1 (ko) 2018-04-19 2018-08-27 주식회사 엘유케이 밀착성, 보습성 및 발림성이 우수한 색조 화장료 조성물 및 그의 제조방법
KR102009008B1 (ko) 2018-08-16 2019-10-21 주식회사 엘유케이 보습 지속력이 우수한 에멀전형 색조 화장료 조성물
KR102633521B1 (ko) * 2023-05-02 2024-02-05 (주) 미영씨앤씨 폴리글리세릴-n 지방산에스테르 기반 방부성 유화제 제조 방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011156030A2 (fr) * 2010-06-11 2011-12-15 Precision Dermatology, Inc. Compositions sous forme de mousse à base d'aérosol émollient riche en huile
KR20120039863A (ko) * 2010-10-18 2012-04-26 (주) 바이오앤텍 나노에멀젼 유화제 및 이를 함유하는 화장료 조성물
KR20130051705A (ko) * 2011-11-10 2013-05-21 코웨이 주식회사 유화 안정성이 우수한 수중유형 나노 에멀젼, 이의 제조방법 및 이를 포함하는 화장료 조성물
KR101448847B1 (ko) * 2013-05-30 2014-10-14 주식회사 코리아나화장품 세라마이드를 함유한 고내상 유중수형 유화 화장료 조성물 및 그 제조 방법
KR101490713B1 (ko) * 2010-12-21 2015-02-06 (주)아모레퍼시픽 제형 안정성 및 피부 안전성이 우수한 저점도 수중유형 화장료 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011156030A2 (fr) * 2010-06-11 2011-12-15 Precision Dermatology, Inc. Compositions sous forme de mousse à base d'aérosol émollient riche en huile
KR20120039863A (ko) * 2010-10-18 2012-04-26 (주) 바이오앤텍 나노에멀젼 유화제 및 이를 함유하는 화장료 조성물
KR101490713B1 (ko) * 2010-12-21 2015-02-06 (주)아모레퍼시픽 제형 안정성 및 피부 안전성이 우수한 저점도 수중유형 화장료 조성물
KR20130051705A (ko) * 2011-11-10 2013-05-21 코웨이 주식회사 유화 안정성이 우수한 수중유형 나노 에멀젼, 이의 제조방법 및 이를 포함하는 화장료 조성물
KR101448847B1 (ko) * 2013-05-30 2014-10-14 주식회사 코리아나화장품 세라마이드를 함유한 고내상 유중수형 유화 화장료 조성물 및 그 제조 방법

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113797105A (zh) * 2021-08-24 2021-12-17 金发拉比妇婴童用品股份有限公司 一种温和安全型复合乳化剂及其应用
CN114681351A (zh) * 2022-04-01 2022-07-01 广州市娇兰化妆品有限公司 一种具有三重作用的类神经酰胺提取物的纳米乳液及其制备方法与应用

Also Published As

Publication number Publication date
KR102541257B1 (ko) 2023-06-12
KR20170124320A (ko) 2017-11-10

Similar Documents

Publication Publication Date Title
WO2017191924A1 (fr) Composition de nano-émulsion contenant un émulsifiant à base de polyglycéryle
JP4825849B2 (ja) ゲル状組成物
JP5351376B2 (ja) 水中油型乳化化粧料
US9456965B2 (en) Oil-in-water emulsified skin cosmetic
JP2003523373A (ja) ゲル化された水性化粧品組成物
EP1267830B1 (fr) Procede a cisaillement eleve/pression elevee pour la preparation de dispersions contenant des ingredients actifs au plan physiologique
US9132091B2 (en) Oil-in-water type nano-emulsion composition and method for preparing same
US20100055220A1 (en) Skin external preparation in the form of water-in-oil emulsion comprising ceramide
US20080226708A1 (en) Silicone Vesicles Containing Actives
KR20110103456A (ko) 실리콘 페이스트 조성물
JP4577721B2 (ja) 化粧料
WO2017003130A1 (fr) Composition cosmétique eau-dans-huile comprenant une poudre polyédrique poreuse
US5711936A (en) Ultramulsion based ingestible compositions
WO2014100633A1 (fr) Compositions topiques comportant des fluides ioniques
WO2007039974A1 (fr) Lotion en émulsion
US20110223120A1 (en) Compositions Having a Plurality of Discrete Emulsions
US20030215470A1 (en) Compositions and methods for preparing dispersions of thickened oils
KR100285004B1 (ko) 지질소낭및90%이상중화된가교결합폴리(2-아크릴아미도-2-메틸프로판술폰산)을기재로한조성물
US20040018250A1 (en) Methods for preparing high pressure/high shear dispersions containing waxes and other semi-solids and oils
JP4171333B2 (ja) 水中油型多相乳化組成物
WO2017003080A1 (fr) Solution de dispersion contenant des microparticules lipidiques solides d'un système exempt de tensioactif, et composition cosmétique l'utilisant
WO2015137647A1 (fr) Composition cosmétique en émulsion sans émulsifiant
WO2022145808A1 (fr) Composition cosmétique de type huile-dans-eau comprenant un agent gélifiant dans l'huile et son procédé de préparation
JP2007106694A (ja) 皮膚外用剤
WO2020145743A1 (fr) Composition d'émulsion pour produits cosmétiques et composition cosmétique la comprenant

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17792826

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17792826

Country of ref document: EP

Kind code of ref document: A1